GARD: Genomic allergen rapid detection

Malin Lindstedt; Kathrin Stephanie Zeller; Henrik Johansson; Carl Borrebaeck

doi:10.1007/978-3-319-50353-0_27

GARD: Genomic allergen rapid detection

Malin Lindstedt, Kathrin Stephanie Zeller, Henrik Johansson, Carl Borrebaeck

Department of Immunotechnology

SenzaGen AB

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Abstract

Genomic allergen rapid detection (GARD) is an in vitro assay for the prediction of skin sensitizing capacity of chemicals. The GARD assay monitors changes in the expression of 196 genes, termed the GARD prediction signature. In short, MUTZ-3 cells, representing a well-characterized in vitro model of human dendritic cells (DCs), are exposed to the test substances for 24 h. After RNA extraction and analysis of expression levels, compounds are predicted as either sensitizers or non-sensitizers by a support vector machine model. Due to high information content, the test can deliver novel insights into pathway utilization and potency. Based on blinded test evaluations, GARD has been shown to have an accuracy of 89%.

Original language	English
Title of host publication	Alternatives for Dermal Toxicity Testing
Publisher	Springer International Publishing
Pages	393-403
ISBN (Electronic)	9783319503530
ISBN (Print)	9783319503516
DOIs	https://doi.org/10.1007/978-3-319-50353-0_27
Publication status	Published - 2017

Subject classification (UKÄ)

Pharmacology and Toxicology

Free keywords

Biomarker signatures
Dendritic cells
Human
In vitro assay
Sensitization

Access to Document

10.1007/978-3-319-50353-0_27

Cite this

@inbook{540bbf6e890142a7b84b32bf86574867,

title = "GARD: Genomic allergen rapid detection",

abstract = "Genomic allergen rapid detection (GARD) is an in vitro assay for the prediction of skin sensitizing capacity of chemicals. The GARD assay monitors changes in the expression of 196 genes, termed the GARD prediction signature. In short, MUTZ-3 cells, representing a well-characterized in vitro model of human dendritic cells (DCs), are exposed to the test substances for 24 h. After RNA extraction and analysis of expression levels, compounds are predicted as either sensitizers or non-sensitizers by a support vector machine model. Due to high information content, the test can deliver novel insights into pathway utilization and potency. Based on blinded test evaluations, GARD has been shown to have an accuracy of 89%.",

keywords = "Biomarker signatures, Dendritic cells, Human, In vitro assay, Sensitization",

author = "Malin Lindstedt and Zeller, {Kathrin Stephanie} and Henrik Johansson and Carl Borrebaeck",

year = "2017",

doi = "10.1007/978-3-319-50353-0_27",

language = "English",

isbn = "9783319503516",

pages = "393--403",

booktitle = "Alternatives for Dermal Toxicity Testing",

publisher = "Springer International Publishing",

address = "Switzerland",

}

TY - CHAP

T1 - GARD

T2 - Genomic allergen rapid detection

AU - Lindstedt, Malin

AU - Zeller, Kathrin Stephanie

AU - Johansson, Henrik

AU - Borrebaeck, Carl

PY - 2017

Y1 - 2017

N2 - Genomic allergen rapid detection (GARD) is an in vitro assay for the prediction of skin sensitizing capacity of chemicals. The GARD assay monitors changes in the expression of 196 genes, termed the GARD prediction signature. In short, MUTZ-3 cells, representing a well-characterized in vitro model of human dendritic cells (DCs), are exposed to the test substances for 24 h. After RNA extraction and analysis of expression levels, compounds are predicted as either sensitizers or non-sensitizers by a support vector machine model. Due to high information content, the test can deliver novel insights into pathway utilization and potency. Based on blinded test evaluations, GARD has been shown to have an accuracy of 89%.

AB - Genomic allergen rapid detection (GARD) is an in vitro assay for the prediction of skin sensitizing capacity of chemicals. The GARD assay monitors changes in the expression of 196 genes, termed the GARD prediction signature. In short, MUTZ-3 cells, representing a well-characterized in vitro model of human dendritic cells (DCs), are exposed to the test substances for 24 h. After RNA extraction and analysis of expression levels, compounds are predicted as either sensitizers or non-sensitizers by a support vector machine model. Due to high information content, the test can deliver novel insights into pathway utilization and potency. Based on blinded test evaluations, GARD has been shown to have an accuracy of 89%.

KW - Biomarker signatures

KW - Dendritic cells

KW - Human

KW - In vitro assay

KW - Sensitization

UR - http://www.scopus.com/inward/record.url?scp=85042614031&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-50353-0_27

DO - 10.1007/978-3-319-50353-0_27

M3 - Book chapter

AN - SCOPUS:85042614031

SN - 9783319503516

SP - 393

EP - 403

BT - Alternatives for Dermal Toxicity Testing

PB - Springer International Publishing

ER -

GARD: Genomic allergen rapid detection

Abstract

Subject classification (UKÄ)

Free keywords

Access to Document

Other files and links

Fingerprint

Cite this